- Home
- UCAR vs MCRB Comparison
UCAR vs MCRB Comparison
Compare UCAR & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UCAR | MCRB |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 41.2M |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | UCAR | MCRB |
|---|---|---|
| Price | $4.00 | $2.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 68.0K | 50.7K |
| Earning Date | 10-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.04 | $3.35 |
| 52 Week High | $8.99 | $29.98 |
Technical Indicators
Market Signals| Indicator | UCAR | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 21.17 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $5.80 |
| Average True Range (ATR) | 0.00 | 0.33 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.